MNG756
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.334
- PANCREAS_BETA_CELLS+0.325
- OXIDATIVE_PHOSPHORYLATION+0.320
- COAGULATION+0.286
- MYOGENESIS+0.239
- XENOBIOTIC_METABOLISM+0.238
- FATTY_ACID_METABOLISM+0.218
- ADIPOGENESIS+0.198
- CHOLESTEROL_HOMEOSTASIS+0.192
Top 10 suppressed
- MITOTIC_SPINDLE-0.570
- G2M_CHECKPOINT-0.546
- E2F_TARGETS-0.520
- PROTEIN_SECRETION-0.388
- INTERFERON_ALPHA_RESPONSE-0.367
- UV_RESPONSE_DN-0.362
- MYC_TARGETS_V2-0.321
- PI3K_AKT_MTOR_SIGNALING-0.306
- ANDROGEN_RESPONSE-0.264
- INTERFERON_GAMMA_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.849 |
| 2 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.826 |
| 3 | TCGA-KQ-A41P-01A-12R-A33J-07 | — | — | 0.817 |
| 4 | TCGA-XF-A8HF-01A-11R-A36F-07 | — | — | 0.816 |
| 5 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.803 |
| 6 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.790 |
| 7 | TCGA-DK-A2I1-01A-11R-A180-07 | — | — | 0.790 |
| 8 | TCGA-Z7-A8R5-01A-42R-A41B-07 | — | B | 0.782 |
| 9 | TCGA-S5-A6DX-01A-11R-A31N-07 | — | — | 0.773 |
| 10 | TCGA-WT-AB44-01A-11R-A41B-07 | — | B | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.334 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.325 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.286 | Binimetinib | — uncovered |
| MYOGENESIS | 0.239 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.238 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.218 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.198 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.192 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.191 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.144 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.114 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.078 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.058 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| COMPLEMENT | 0.048 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.034 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.022 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.017 | Idelalisib | — uncovered |